FDA accepts anti-arrhythmic agent NDA from Prism, Cydex

TriMed Staff | | Health Imaging | Screening
CyDex Pharmaceuticals has reported that Prism Pharmaceuticals’ Nexterone, which is based on the patent-protected CyDex Captisol technology platform, has received new drug application (NDA) approval from the FDA.

The Lenexa, Kansas-based CyDex said Nexterone is its first proprietary product to achieve an NDA approval. According to the company, Captisol technology improves the water solubility and stability of active pharmaceutical ingredients. The tool allowed the King of Prussia, Pa.-based Prism to develop a formulation of the anti-arrhythmic agent Amiodarone IV (originally marketed as Cordarone Intravenous) without the cosolvents polysorbate 80 and benzyl alcohol that are used in the innovator product. 

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.